Life sciences / secure diligence / buyer's field guide
Choose by the review you must run: a small-team financing, multi-party licensing process, operational diligence or IPO. Compare access control, evidence retrieval, room upkeep and total cost using the same test. Provider descriptions below are sourced but not independently tested
Start with the decision ↘01 / the basics
A data room is where a company opens its confidential record to people outside the company for a defined review, then closes it again. It is a disclosure tool, not the place the work is done
A secure online space holding copies of the documents a counterparty needs to review: financials, cap table, contracts, clinical and regulatory files, manufacturing and quality records, patents. Each reviewer sees only what they have been given, and every view and download is logged
Not a replacement for the trial master file, quality system or electronic health recordA single financing or partnering process can involve investors, pharma business development, scientific and IP reviewers, counsel, auditors and, in an IPO, underwriters. Each needs a different slice of the same record, often on the same timeline
Permissions by party keep one folder structure serving every readerUnpublished trial data, CMC and process details, and licence terms are usually released in stages: summaries first, full packages after terms or exclusivity. Competing partners in the same process must never see each other's access or questions
Watermarks, view-only files and revocable access support staged disclosureAfter a financing, licence or offering, the company may need to show exactly which version of a document each party saw and when. Activity logs and a closing archive answer that question without reconstructing email threads
Keep the export: it becomes part of the deal fileA data room is a controlled online space where a company shares confidential documents with outside reviewers during a financing, licensing deal, acquisition or IPO. Access is granted by party, documents can be restricted or watermarked, and the room keeps a record of who opened what and when
Because several outside teams review the same sensitive record at once: investors, pharma business development, counsel, auditors and underwriters. Clinical, manufacturing and intellectual-property files need to be opened in stages, kept apart between competing counterparties, and traceable after the deal
Sometimes. A small angel or seed round with a handful of readers can often run from a well-organized shared folder. The case for a data room grows with the number of outside parties, the sensitivity of the files and the need to prove later exactly what each reviewer saw
02 / decision framework
A data room is a controlled disclosure layer, not a trial master file, an electronic health record or the primary research archive. Select for the counterparties and document transitions that actually exist in your process
Prioritize fast setup, staged access, NDA handling, an understandable bill and exportable engagement history. Before buying, test whether the founder or CFO can update the room without a service team
Typical readers: investors, counsel, boardPrioritize per-party permissions, watermarking, restrictions on copying, document-version control and a reliable record of who reviewed which package. Test clean separation between competing partners
Typical readers: pharma BD, scientific and IP diligence teamsTrace design and quality files or payer and facility records back to their source systems. Test external reviewer permissions and whether the room can keep restricted patient or personnel material out of broad access
Typical readers: acquirers, regulatory, quality, counselPrioritize a stable index, large-file handling, granular access, comment coordination, exportable logs and an archive that survives the offering. Ask counsel and bankers to test the actual S-1 support workflow
Typical readers: underwriters, auditors, counsel, managementFor an always-on licensing room, compare Firmex and ShareVault. A team seeking clinical-data archiving should separately inspect Ideals. These are provider-described starting points, not performance judgments; run the same trial for every candidate
03 / provider records
These are candidate records, not a ranking or a complete market census. Each entry links to a current provider page, names the use case described there, and leaves a buyer-validation question open. Provider-stated does not mean independently verified
About the scale lines. Each repeats a figure the provider publishes on its own page, in its own unit (companies, users, teams, deals or projects). They are not verified and cannot be compared with one another
Datasite's healthcare and life-science page describes M&A, fundraising, partnership and regulatory-communication processes, and lists sell-side, buy-side, financing, IPO, restructuring, licensing and secure-repository workflows
Scale it states Says 4 of the top 5 global M&A deals use it
Buyer check Validate the actual project configuration, support model and commercial terms for your deal
Provider sector page ↗Firmex describes always-on rooms for fundraising, licensing and clinical-trial-related sharing, with access controls and document activity reports
Scale it states Says 223,000+ companies and 1.4 million+ users, 189,000 projects, 180+ countries
Buyer check Test investor and licensing-partner separation with a real document package
Provider sector page ↗Ideals presents life-sciences use cases around clinical-trial collaboration and searchable clinical archives, alongside permission and audit-trail features
Scale it states Says two million leaders use it globally
Buyer check Determine whether your need is transaction diligence, clinical archive, or both; evaluate them separately
Provider sector page ↗Intralinks describes a life-sciences platform for M&A, licensing, alliances and partnerships, and capital raising, with AI-assisted document handling and integrated redaction
Scale it states Says 25+ years in life sciences, 90+% of the F1000 in the sector, US$35+ trillion of transactions
Buyer check Have the deal team test its project setup, review workflow and archive handoff
Provider sector page ↗Peony describes NDA-gated access, dynamic watermarks, granular folder and file permissions, audit logs and AI document Q&A across biotech fundraising, licensing review and CMC, clinical and patent files. These are Peony's own claims, not third-party findings
Scale it states Says 8,000+ teams since 2021, including funds it says manage over US$44.7B in assets (from its pricing page)
Buyer check Verify the current plan, feature availability, export needs and reviewer workflow in a live trial
Provider sector page ↗ShareVault describes rooms for biotech, pharma, medtech, CROs and diagnostics, spanning licensing, fundraising, M&A, quality documentation, regulatory review and board communication
Scale it states Says more than 8k active users, and states it holds the exclusive endorsement of BIO
Buyer check Test stage-specific disclosure and permissions for several counterparties
Provider sector page ↗04 / controlled trial
Run the same short test in each candidate room using a representative, sanitized package rather than a generic sales demo
Create separate investor or partner groups, change a user's permissions and revoke access; inspect what remains visible in activity history
Upload a protocol, a redacted financial schedule and a revised license. Ask an unfamiliar reviewer to locate the right version and cite it
Time a content update, permission review and export. Record every step that requires vendor help and what happens after the deal closes
Ask for a written quote using your admin count, project count, storage, term, guest access and archive needs; compare the same scope
05 / method and limits
Included providers had a current official page explicitly describing a life-sciences, biotech, healthcare or related diligence use case. The first cohort was checked on 23 September 2026 and every record was re-read against its official page in October 2026; Datasite's source was replaced because its earlier brochure link had been removed. Records appear alphabetically and use the same three fields: stated use, buyer check and source. Absence does not imply poor fit
Capabilities, security claims and sector descriptions are Provider-stated. Not independently tested. This page does not establish compliance, comparative performance, pricing or suitability for a particular transaction. Corrections should be grounded in an official source and date
06 / earlier readings
Provider pages change. The September readings are kept so a change can be traced, with what moved in October. The records above are current
September 2026 reading. Datasite's sector brochure describes diligence, partnerships, licensing, fundraising and IPO workflows across biotech, pharma, devices and healthcare services
Source then: https://www.datasite.com/docs/default-source/brochures/datasite-for-healthcare-life-sciences.pdf?sfvrsn=2403a51a_2 (no longer available when re-checked in October 2026, shown as text only)
Now. Datasite's healthcare and life-science page describes M&A, fundraising, partnership and regulatory-communication processes, and lists sell-side, buy-side, financing, IPO, restructuring, licensing and secure-repository workflows
September 2026 reading. Firmex describes always-on rooms for fundraising, licensing and clinical-trial-related sharing, with access controls and document activity reports
Source then: https://www.firmex.com/virtual-data-room/industries/firmex-for-biotech-pharma/
Now. Firmex describes always-on rooms for fundraising, licensing and clinical-trial-related sharing, with access controls and document activity reports
September 2026 reading. Ideals presents life-sciences use cases around clinical-trial collaboration and searchable clinical archives, alongside permission and audit-trail features
Source then: https://www.idealsvdr.com/virtual-data-room-life-sciences/
Now. Ideals presents life-sciences use cases around clinical-trial collaboration and searchable clinical archives, alongside permission and audit-trail features
September 2026 reading. Intralinks describes a life-sciences deal platform for confidential collaboration and transaction diligence, including business-development and licensing processes
Source then: https://www.intralinks.com/industries/life-sciences
Now. Intralinks describes a life-sciences platform for M&A, licensing, alliances and partnerships, and capital raising, with AI-assisted document handling and integrated redaction
September 2026 reading. Peony describes NDA-gated access, watermarks, granular permissions, audit trails and AI-supported document search for biotech fundraising and licensing review. These are Peony's own claims, not third-party findings
Source then: https://www.peony.ink/solutions/biotech
Now. Peony describes NDA-gated access, dynamic watermarks, granular folder and file permissions, audit logs and AI document Q&A across biotech fundraising, licensing review and CMC, clinical and patent files
September 2026 reading. ShareVault describes rooms for biotech, pharma, medtech and CROs, spanning licensing, fundraising, regulatory review and other confidential collaborations
Source then: https://sharevault.com/industries/life-sciences/
Now. ShareVault describes rooms for biotech, pharma, medtech, CROs and diagnostics, spanning licensing, fundraising, M&A, quality documentation, regulatory review and board communication
The September snapshot is also available as JSON